Assessment cycle 2023 Q1 — page 11
Documents ratified in the 2023 Q1 assessment cycle, which ran from 1 January 2023 to 31 March 2023 and was ratified on 18 March 2023.
Documents ratified
-
Randomised crossover, phase 1 study of Semaglutide in obesity and prediabetes over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low29 Jun 2023 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low01 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low17 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low12 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low17 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low07 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The…
Very low13 May 2023 -
Randomised crossover, phase 1 study of Tirzepatide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result…
Very low17 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low20 Jun 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low14 Sep 2023 -
Randomised crossover, phase 1 study of Tirzepatide in type 2 diabetes and cardiovascular over as stated in the parent protocol. The Institute holds no reported primary…
Very low11 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low27 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Liraglutide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low14 Oct 2023 -
Randomised crossover, phase 1 study of Liraglutide in adolescent obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low26 Nov 2023 -
Phase 1 ascending dose, phase 1 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low03 Aug 2023 -
Observational, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low25 Jun 2023 -
Single-arm open-label, phase 3 study of Dulaglutide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low15 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes and chronic kidney disease over as stated in the parent protocol. The…
Very low20 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low22 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low27 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low20 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low26 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low21 Mar 2024 -
Randomised crossover, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low17 Feb 2024 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low25 Apr 2024 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low28 May 2023 -
Observational, phase 3 study of Semaglutide, oral in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low08 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of SS-31 (elamipretide) in mitochondrial disease over as stated in the parent protocol. The Institute holds…
Very low15 Aug 2023 -
Observational, phase 3 study of SS-31 (elamipretide) in mitochondrial disease over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low08 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no…
Very low24 Nov 2023 -
Phase 1 ascending dose, phase 1 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported primary…
Very low26 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low07 Sep 2023 -
Single-arm open-label, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over open-label extension of the parent trial. The Institute holds no reported primary…
Very low07 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and chronic kidney disease and type 2 diabetes over as stated in the parent…
Very low19 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low22 Apr 2024 -
Phase 1 ascending dose, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low17 Jan 2024 -
Phase 1 ascending dose, phase 1 study of Retatrutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low19 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low16 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of CagriSema (cagrilintide with semaglutide) in type 2 diabetes and obesity over as stated in the parent…
Very low27 Apr 2023 -
Randomised crossover, phase 1 study of Cagrilintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low06 Jun 2023
page 11 of 13